Abstract
Acute myeloid leukemia (AML) is primarily a disease of older adults. These patients may not be candidates for intensive treatment, and there has been an ongoing need for treatment options for this group. We review the use of glasdegib, a hedgehog-pathway inhibitor available for use in combination with low-dose cytarabine (LDAC).Data Sources: PubMed and relevant congress abstracts were searched using the term "glasdegib". In addition, based on our experience with glasdegib, we considered treatment aspects of particular relevance to pharmacists and advanced practitioners.Data Summary: In a randomized phase II study, the combination of glasdegib plus LDAC demonstrated superior overall survival versus LDAC alone (hazard ratio 0.51, 80% confidence interval 0.39-0.67, p = 0.0004). The trial reported adverse events (AEs) of special relevance for older patients, such as hematologic events, gastrointestinal toxicity, and fatigue, as well as AEs associated with Hh-pathway inhibitors (alopecia, muscle spasms, dysgeusia). Educating patients about typical AEs can facilitate adherence as well as early AE identification and proactive management. For LDAC, which is a long-established therapy in AML, various stages of delivery need consideratio...Continue Reading
References
Jan 26, 2006·Cancer·Hagop KantarjianElihu Estey
Feb 23, 2007·Cancer·Alan K BurnettKeith Wheatley
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Amanda F CashenJohn F DiPersio
Aug 31, 2010·Oncogene·K C S QueirozC A Spek
Jun 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hagop M KantarjianChristopher Arthur
Oct 2, 2012·Clinical Journal of Oncology Nursing·Marlene K Wilken, Bernadette A Satiroff
Jul 11, 2013·Blood·Alan K BurnettUNKNOWN UK National Cancer Research Institute AML Working Group
Jun 20, 2014·Cancer Chemotherapy and Pharmacology·M Naveed ShaikWendy J Levin
May 20, 2015·Blood·Hervé DombretHartmut Döhner
Dec 22, 2015·The Lancet. Haematology·Giovanni MartinelliCatriona Jamieson
Apr 22, 2016·Leukemia Research·Jennifer E VaughnRoland B Walter
Oct 30, 2016·Cancer Science·Nobuaki FukushimaTomoki Naoe
Aug 4, 2016·Oncotarget·Giorgia GiordaniRoberto Bernardoni
Aug 12, 2016·The Oncologist·Mario E LacoutureRainer Kunstfeld
Nov 17, 2017·Blood·Gregory A Abel, Heidi D Klepin
Mar 1, 2018·British Journal of Clinical Pharmacology·M Naveed ShaikRobert R LaBadie
Jul 11, 2018·Cancers·Kah Poh Loh, Heidi D Klepin
Jul 29, 2018·Annals of Hematology·F HoferR Stauder
Dec 12, 2018·Cancer Chemotherapy and Pharmacology·Naveed ShaikRobert R LaBadie
Dec 13, 2018·Dermatology and Therapy·Evelyn Yu-Xin TayMatthew Sze-Wei Yeo
Dec 18, 2018·Leukemia·Jorge E CortesMichael Heuser
Jan 27, 2019·ClinicoEconomics and Outcomes Research : CEOR·Anna ForsytheBhakti Arondekar
Feb 5, 2019·Current Medical Research and Opinion·Bruno C MedeirosL Elise Horvath Walsh
May 9, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kelly J NorsworthyRichard Pazdur
Sep 5, 2019·Cancer·Amer M ZeidanRong Wang
Sep 14, 2019·Future Oncology·Jorge E CortesMikkael A Sekeres
Mar 29, 2020·Blood·Andrew H WeiPanayiotis Panayiotidis